Humanigen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.humanigen.com
Clinical Trials
8
Active:0
Completed:5
Trial Phases
3 Phases
Phase 1:4
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (50.0%)Phase 2
3 (37.5%)Phase 3
1 (12.5%)Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
Phase 3
- Conditions
- Coronavirus Disease 2019 (COVID-19) Pneumonia
- Interventions
- Biological: LenzilumabDrug: Standard of Care
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 520
- Registration Number
- NCT04351152
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸University of California, Irvine, Irvine, California, United States
🇺🇸University of Southern California (USC) Medical Center, Los Angeles, California, United States
Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02546284
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Mayo Clinic Cancer Center Clinical Research, Rochester, Minnesota, United States
Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment
Phase 2
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Biological: KB001-ADrug: Placebo Comparator
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT01695343
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Phase 2
Completed
- Conditions
- Moderate-to-Severe Asthma
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2015-02-02
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT01603277
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase 1
Suspended
- Conditions
- Myelodysplastic Syndrome (MDS)Myelofibrosis (MF)
- Interventions
- Drug: KB004, Monoclonal Antibody
- First Posted Date
- 2010-09-29
- Last Posted Date
- 2015-11-17
- Lead Sponsor
- Humanigen, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT01211691
- Prev
- 1
- 2
- Next
News
No news found